Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter Financial Results
ESPERION THERAP (NASDAQ: ESPR) Delayed: 3.16 --0 (-0%)
Previous Close $3.16    52 Week High $30.41 
Open $3.16    52 Week Low $9.40 
Day High $3.17    P/E N/A 
Day Low $3.15    EPS $-21.87 
Volume 5,646,804